Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.37 |
| ▸ | CPB1 | P15086 | 1/20 | 0.37 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7074055 | 0.89 | CPB2 (0.40) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL10777853 | 0.89 | CPB2 (0.40) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL14344575 | 0.88 | CPB2 (0.38) | CPB2CPB1 | |
| SCHEMBL147911 | 0.86 | CPB2 (0.38) | CPB2CPB1GPR142ALDH1A1CYP1A2 | |
| SCHEMBL28558505 | 0.86 | CPB2 (0.38) | CPB2CPB1GPR142ALDH1A1CYP1A2 | |
| SCHEMBL9847306 | 0.86 | MEN1 (0.34) | — | |
| SCHEMBL29854195 | 0.85 | CPB2 (0.31) | CPB2CPB1 | |
| SCHEMBL933574 | 0.85 | CPB2 (0.37) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL201189 | 0.85 | CPB2 (0.42) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL11301850 | 0.85 | CPB2 (0.37) | CPB2CPB1ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3693 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140903-A1 | COMPOSITION OF CD40-BINDING MOLECULE AND PHARMACEUTICAL USE THEREOF | 苏州盛迪亚生物医药有限公司 | 2024-07-04 | — | — | WO | claimed |
| WO-2024141054-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FUSION PROTEIN AND USE THEREOF | 苏州康宁杰瑞生物科技有限公司 | 2024-07-04 | — | — | WO | claimed |
| WO-2024120518-A1 | IL-17A ANTIBODY FORMULATION AND USE THEREOF | 上海华奥泰生物药业股份有限公司 | 2024-06-13 | — | — | WO | claimed |
| WO-2024088293-A1 | COMPOSITION COMPRISING ANTI-MASP2 ANTIBODY, AND PHARMACEUTICAL USE | 江苏恒瑞医药股份有限公司 | 2024-05-02 | — | — | WO | claimed |
| CN-117942300-A | Liquid formulations comprising anti-IL-17 antibodies | 甘李药业股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-111375059-B | anti-GITR antibody pharmaceutical composition and application thereof | 江苏恒瑞医药股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-112543647-B | TIM3 antibody pharmaceutical composition and application thereof | 江苏恒瑞医药股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-113713094-B | anti-IL-6R antibody pharmaceutical composition and application thereof | 江苏恒瑞医药股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| US-20240024498-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE, AND USE OF PHARMACEUTICAL COMPOSITION | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2024-01-25 | — | — | US | claimed |
| US-20240016931-A1 | ANTI-TSLP ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2024-01-18 | — | — | US | claimed |
| CN-102281901-A | Therapeutic protein formulations | — | 2011-12-14 | — | — | CN | claimed |
| EP-2371388-A2 | Antibody formulations | Genentech, Inc. (US) | 2011-10-05 | — | — | EP | claimed |
| EP-2358393-A1 | THERAPEUTIC PROTEIN FORMULATIONS | F.HOFFMANN-LA ROCHE AG (CH) | 2011-08-24 | — | — | EP | claimed |
| CN-101084015-B | Antibody formulations in histidine-acetate buffer | GENENTECH INC | 2011-08-10 | — | — | CN | claimed |
| WO-2010059787-A1 | THERAPEUTIC PROTEIN FORMULATIONS | GENENTECH, INC. (US) | 2010-05-27 | — | — | WO | claimed |
| US-20100015157-A1 | ANTIBODY FORMULATIONS | GENENTECH, INC. (US) | 2010-01-21 | — | — | US | claimed |
| CN-101084015-A | Antibody formulations in histidine-acetate buffer | GENENTECH INC (US) | 2007-12-05 | — | — | CN | claimed |
| EP-1802344-A2 | ANTIBODY FORMULATION IN HISTIDINE-ACETATE BUFFER | Genentech, Inc. (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2006044908-A2 | ANTIBODY FORMULATION IN HISTIDINE-ACETATE BUFFER | GENENTECH, INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-20060088523-A1 | Antibody formulations | GENENTECH, INC. | 2006-04-27 | — | — | US | claimed |